Revio powers research into male infertility and rare diseases at the University Hospital of Münster Page 1

Revio’s Highly Accurate Long-Read Sequencing Data Will Support the German National Genome Initiative and Provide Data to the International Male Infertility Consortium

MENLO PARK, Calif., Sept. 4, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with the University Hospital of Münster to use long-read whole genome sequencing to significantly advance research into male infertility and rare diseases. By implementing PacBio’s Revio HiFi sequencing system, researchers at Münster will obtain highly accurate genomic data essential for addressing complex genetic issues associated with male infertility, including the Y chromosome.